The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
September 18th 2024
The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.
September 7th 2024
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
TLANDO, an Oral Option for TRT for Men, Approved by US FDA
March 29th 2022On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.
Study Examines Link Between Increased Sedentary Time, Precocious Puberty Diagnoses in Italy
March 15th 2022After previous studies found an increase in the diagnosis of central precocious puberty, investigators launched a new study to assess whether decreases in physical activity might be linked to the increased diagnosis rate.
History of Spontaneous Abortion Linked to Increased Risk of Gestational Diabetes
March 7th 2022An analysis of data from more than 100k pregnant women suggests a history of spontaneous abortion was associated with an 18% increase in risk of subsequent gestational diabetes, with a history of multiple spontaneous abortions associated with an even greater risk.
Endocrine Month in Review: February 2022
February 26th 2022Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. February's month in review features a pair of diabetes tech approvals from the FDA, a video program, and a KOL interview discussing rising death toll attributable to diabetes.
Bardoxolone Rejected by FDA for CKD Caused by Alport Syndrome
February 26th 2022Announced by Reata Pharmaceuticals on February 25, the Complete Response Letter from the FDA for bardoxolone methyl comes a little over 2 months after an FDA advisory committee voted unanimously against approval of the once-daily, orally administered activator of Nrf2.
Endocrine Case Report: Cirrhotic with Epigastric Pain
February 23rd 2022The latest case report from Brady Pregerson, MD, features a man in his 60s with a history of diabetes and cirrhosis presenting with 2 weeks of right upper quadrant pain with constipation and 2 days of vomiting. Can you determine the correct diagnosis?
Study Details Causal Effect of Obesity on Diabetic Nephropathy
February 22nd 2022Data from an analysis of more than 150,000 patients suggests increased BMI was associated with more than a 3-fold increase in odds of diabetic nephropathy in patients with type 2 diabetes, but this effect was more apparent in women who experienced a 14-fold increase in odds of diabetic nephropathy.